Gupta, Gaurav
Prof. Dr. Gaurav Gupta is an Adjunct Research Professor at the Centre for Global Health Research at Ajman University, UAE and the Centre for Research Impact & Outcome at Chitkara College of Pharmacy, Chitkara University, Rajpura. Dr. Gupta's research interests lie in molecular mechanisms of receptor biology, epigenetics, and behavioral pharmacology. He has a distinguished record of over 700 publications in peer-reviewed international journals, amassing a cumulative impact factor of over 5000. His scholarly work has garnered more than 20,000 citations, reflecting his significant contributions to the field. With an h-index of 67 and an i10-index of 400, Dr. Gupta's research has been widely recognized and respected within the scientific community. His academic and research achievements have earned him a place among the world's top 2% of scientists, a distinction he has held since 2020, as per the Stanford University database. This recognition underscores his global impact and influence in the scientific community. Dr. Gupta has also authored and edited several influential books, including titles such as "Targeting Epigenetics in Inflammatory Lung Diseases" and "Microbiome in Inflammatory Lung Diseases," published by Springer. Throughout his career, Dr. Gupta has demonstrated a solid commitment to innovation in education and research. He has been actively involved in designing new experiments in pharmacology to enhance student learning and has embraced e-learning tools to foster student engagement. His teaching methodology incorporates a blend of traditional and modern techniques, ensuring that his students are well-prepared for the challenges of the pharmaceutical sciences. Dr. Gupta's achievements have been recognized with several awards, including the Young Scientist Award 2019 and the Innovative Researcher Award from the Association of Pharmacy Professionals in 2017.
Bhat, Asif Ahmad
Dr. Asif Ahmad Bhat is an Assistant Professor at the Uttaranchal Institute of Pharmaceutical Sciences, Dehradun, India. His research interests include pharmacological screening methods, neuropharmacology, cancer therapeutics, and non-coding RNAs. Dr. Bhat has an impressive record of over 50 publications in peer-reviewed international journals, including those by Elsevier, Wiley, and Springer, with over 1500 citations, reflecting his substantial contributions to the field. Dr. Bhat's scholarly work has received recognition in the scientific community, with multiple high-impact publications exploring the pyroptotic role of Caspase-3/GSDME in cancer, the molecular role of Sirtuin 1 in aging, and polysaccharide-based nanomedicines for lung cancer. His work has been cited widely, highlighting his influence in advancing pharmaceutical sciences. Dr. Bhat has been recognized with several awards, including Excellence in Research (2023) and Best e-Poster Presenter at the International Conference on Health Science and Technology (AICHST) in Malaysia (2023). He is also a certified GPAT (2017) achiever with an AIR 140.
MacLoughlin, Ronan
Dr Ronan MacLoughlin, PhD MBS, is currently director of Research and Development, Science and Emerging Technologies in Aerogen limited and Irish medical device company specializing in respiratory drug delivery. He has more than 25 years of experience in the design and development of aerosol drug delivery systems and drug/device combination products. He currently has more than 120 articles, and multiple conference presentations and conference papers combined with several patents. He holds the position of adjunct associate professor in Trinity College Dublin's (Ireland) Department of Pharmaceutics and Pharmaceutical Technology, honorary Senior Lecturer in the Royal College of Surgeons Ireland (RCSI), nonexecutive director on the board of several startup and scaling Med tech and pharmaceutical companies. Additionally, he is currently chair of the pediatric and cystic fibrosis working group within the International Society for aerosols in medicine. In 2024 he was honored with the Thomas T Mercer award, recognizing Dr MacLoughlin's excellence in the areas of pharmaceutical aerosols and inhalable materials.development of drug delivery systems and drug device combinations, he has >220 collaborative publications,
as well as 12 granted patents.
His most recent focus has been on enabling several clinical programs making use of aerosolised prophylactics
and therapeutics for COVID-19, and his work on delivery of inhaled vaccines has resulted in the
world's first approval for an orally inhaled vaccine for COVID-19 (Convidecia Air). His contribution to the
state of the art in fugitive medical and patient-derived aerosols was central to the evolution of several
critical care consensus statements around the safe use of aerosol therapy during the COVID-19 pandemic.
